Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer

Oncologist

Volumn 17, Issue 4, 2012, Pages 513-524

  Strickler, John H ^a   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Combination drug therapy; Drug toxicity; Vascular endothelial growth factor

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CD31 ANTIGEN; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MITOMYCIN; NEUROPILIN; OXALIPLATIN; PLACEBO; PROTEIN P53; THROMBOSPONDIN 2; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGINA PECTORIS; BLEEDING; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REGIMEN; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; HEART INFARCTION; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TUMOR GROWTH; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860169991     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0003     Document Type: Review

References (99)

1. Genentech, Inc. Avastin®(bevacizumab) [package insert]. Available at http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf, accessed December 14, 2011.
2. Borgström P, Bourdon MA, Hillan KJ et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10.
3. Borgström P, Gold DP, Hillan KJ et al. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-4214.
4. Borgström P, Hillan KJ, Sriramarao P et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
5. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
6. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362: 841-844.
7. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996;56:921-924.
8. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95: 1789-1797.
9. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88:1979-1986.
10. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 2006;33(suppl 10): S1-S7.
11. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
12. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
13. Shih T, Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-1802.
14. PR Newswire. Pharmacia Announces Closing of SU5416 (Semaxanib) Clinical Trials. Available at http://www.prnewswire.com/news-releases/pharmacia-announces-closing-of-su5416-semaxanibclinical-trials-75895232.html, accessed December 14, 2011.
15. Sanofi. Zaltrap™ (Aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients. Available at http://en.sanofi.com/Images/26167_20110606_Zaltrap_2_en.pdf, accessed December 14, 2011.
16. AstraZeneca. AstraZeneca Announces Results of Recentin HORIZON II Phase III Trial in Metastatic Colorectal Cancer, 2010. Available at http://www.astrazeneca.com/Media/Press-releases/Article/20100528--AstraZeneca-Announces-Results-of-Recentin-HORIZON-II-, accessed December 14, 2011.
17. Phase-3 Sunitinib Trial in Metastatic Colorectal Cancer Stopped. HemOncToday, July 1, 2009. Available at http://www.hemonctoday.com/article.aspx?rid_41305, accessed December 14, 2011.
18. Hecht JR, Trarbach T, Jaeger E et al. Arandomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 2005;23(16 suppl):3.
19. Koehne C, Bajetta E, Lin E et al. Results of an interim analysis of a multinational randomized, double- blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol 2006;24(18 suppl):3508.
20. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19: 843-850.
21. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, accessed December 14, 2011.
23. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
24. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 2008; 26:689-690.
25. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 2007;25: 4779-4786.
26. Bajetta E, Di Bartolomeo M, Mariani L et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279-287.
27. Borner MM, Bernhard J, Dietrich D et al. Arandomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. Ann Oncol 2005;16:282-288.
28. Cartwright T, Lopez T, Vukelja SJ et al. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2005;5:50-56.
29. Köhne CH, De Greve J, Hartmann JT et al. Irinotecan combined with infusional 5-fluorouracil/ folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008;19:920-926.
30. Patt YZ, Lee FC, Liebmann JE et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: Phase II trial results. Am J Clin Oncol 2007; 30:350-357.
31. Rea DW, Nortier JW, Ten Bokkel Huinink WW et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as firstline therapy for advanced colorectal cancer. Ann Oncol 2005;16:1123-1132.
32. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as firstline treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26: 3523-3529.
33. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-2019.
34. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
35. Hecht JR, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-680.
36. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
37. Schmoll H, Cunningham D, Sobrero A et al. mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, Phase II/III study (HORIZON III) [abstract 5800]. Ann Oncol 2010;21(suppl 8):viii189.
38. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. The Oncologist 2009;14:862-870.
39. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010;28(15 suppl):3596.
40. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009;20:1842-1847.
41. Bendell JC, Bekaii-Saab TS, Cohn AL et al. Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a bevacizumab (BV) observational study. J Clin Oncol 2011;29(4 suppl):480.
42. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
43. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
44. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
45. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28:3191-3198.
46. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727-5733.
47. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400.
48. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: Results of the randomised phase 3MRCCOIN trial. Lancet Oncol 2011;12:642-653.
49. Grothey A, Hart LL, Rowland KM et al. Intermittent oxaliplatin (oxali) administration and timeto- treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol 2008;26(15 suppl): 4010.
50. Tabernero J, Aranda E, Gomez A et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single- agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). J Clin Oncol 2010;28(15 suppl):3501.
51. Yalcin S, Uslu R, Dane F et al. A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer. J Clin Oncol 2011;11(4 suppl):474.
52. ClinicalTrials.gov. Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer. Available at http://www.clinicaltrials.gov/ct2/results?term_NCT00952029, accessed December 15, 2011.
53. ClinicalTrials.gov. Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer. Available at http://www.clinicaltrials.gov/ct2/results?term_NCT00544700, accessed December 15, 2011.
54. ClinicalTrials.gov. Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma. Available at http://www.clinicaltrials.gov/ct2/results?term_NCT00442637, accessed December 15, 2011.
55. Tournigand C, Scheithauer BSW, Andre CLT et al. mFOLFOX-bevacizumab or XELOX-bevaci- zumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. J Clin Oncol 2009;27(15 suppl): 4077.
56. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-5334.
57. ClinicalTrials.gov. Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC). Available at http://www.clinicaltrials.gov/ct2/results?term_NCT00862342, accessed December 15, 2011.
58. ClinicalTrials.gov. Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab. Available at http://www.clinicaltrials.gov/ct2/results?term_NCT00720512, accessed December 15, 2011.
59. ClinicalTrials.gov. A Study of Avastin® (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. Available at http://www.clinicaltrials.gov/ct2/results?term_NCT00700102, accessed December 15, 2011.
60. Chua YJ, Cunningham D. Neoadjuvant treatment of unresectable liver metastases from colorectal cancer. Clin Colorectal Cancer 2006;5:405-412.
61. Bertolini F, Malavasi N, Scarabelli L et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 2011;104:1079-1084.
62. Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101:1033-1038.
63. Wong R, Saffery C, Barbachano Y et al. BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. Eur J Cancer 2009; 7:344-345.
64. Ribero D, Wang H, Donadon M et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin- based chemotherapy for colorectal liver metastases. Cancer 2007;110:2761-2767.
65. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180.
66. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99: 1232-1239.
67. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008;300:2277-2285.
68. Cassidy J, Saltz L, Van Cutsem E et al. Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of over 6,000 patients in randomized phase II and III studies. J Clin Oncol 2010;28(15 suppl):3604.
69. Alcalay A, Wun T, Khatri V et al. Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival. J Clin Oncol 2006; 24:1112-1118.
70. Tebbutt NC, Murphy F, Zannino D et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 2011;22:1834-1838.
71. Berry SR, Cutsem EV, Kretzschmar A et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. J Clin Oncol 2008;26: 4025.
72. Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009;77:113-119.
73. Kabbinavar FF, Hurwitz HI, Yi J et al. Addition of bevacizumab to fluorouracil-based firstline treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27:199-205.
74. Cassidy J, Saltz LB, Giantonio BJ et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010;136:737-743.
75. Kozloff M, Bekaii-Saab TS, Bendell JC et al. Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). J Clin Oncol 2011; 29(15 suppl):3625.
76. Kozloff MF, Berlin J, Flynn PJ et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study. Oncology 2010;78:329-339.
77. Masi G, Loupakis F, Salvatore L et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: A phase 2 trial. Lancet Oncol 2010;11:845-852.
78. ClinicalTrials.gov. A Phase III Randomized Trial of FOLFOXIRI + Bevacizumab Versus FOLFIRI + Bevacizumab as First- Line Treatment for Metastatic Colorectal Cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00719797?term=folfoxiri+bevacizumab&rank_7, accessed December 15, 2011.
79. Riedel F, Gôtte K, Li M et al. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 2002;21:11-16.
80. Saltz LB, Lenz HJ, Kindler HL et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007;25: 4557-4561.
81. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 2001;61:5090-5101.
82. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-1183.
83. Crawford Y, Kasman I, Yu L et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15:21-34.
84. Shojaei F, Wu X, Malik A K et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25:911-920.
85. Li JL, Sainson RC, Shi W et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-11253.
86. Pan Q, Chanthery Y, Liang WC et al. Blocking neuropilin-1 function has an additive effect with anti- VEGF to inhibit tumor growth. Cancer Cell 2007; 11:53-67.
87. Jubb AM, Hurwitz HI, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-227.
88. Hurwitz HI, Yi J, Ince W et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. The Oncologist 2009;14:22-28.
89. Ince WL, Jubb AM, Holden SN et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97: 981-989.
90. Price TJ, Hardingham JE, Lee CK et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011;29:2675-2682.
91. Foernzler D, Delmar P, Kockx M et al. Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC [abstract 374]. Presented at the 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010.
92. Weickhardt AJ, Williams D, Lee C et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. J Clin Oncol 2011;29(15 suppl): 3531.
93. Lieu CH, Tran HT, Jiang Z et al. The association of alternate VEGF ligands with resistance to anti- VEGF therapy in metastatic colorectal cancer. J Clin Oncol 2011;29(15 suppl):3533.
94. Nixon AB, Pang H, Starr M et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. J Clin Oncol 2011;29(15 suppl): 10508.
95. Bernaards C, Hegde P, Chen D et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in meta- static colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. J Clin Oncol 28(15 suppl):10519.
96. Miles D, de Haas S, Dirix L et al. Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer [abstract P2-16-04]. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010.
97. Hurwitz H, Douglas PS, Middleton JP et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 2010; 28(15 suppl):3039.
98. Guan Z, Xu J, Luo R et al. Bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: Efficacy and tolerability results from the ARTIST study [abstract PD-0007]. Ann Oncol 2010;21(suppl 6):vi22.
99. El-Khoueiry AB, Pohl A, Danenberg K et al. Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progressionfree survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol 2009;27(15 suppl):4056.